Evidence map›Paper›PMID 40693238›Full record

ArticleJournal of the National Cancer Center2025

Divergent trends in the burden of esophageal, gastric, and liver cancers in China.

Yongjie Xu, Changfa Xia, Jiachen Wang, Yujie Wu, Wanqing Chen

Abstract read
In one paragraph

Article in Journal of the National Cancer Center, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yongjie XuOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Changfa XiaOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jiachen WangOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yujie WuOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Wanqing ChenOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: While China's socioeconomic transformation has driven divergent trends in gastrointestinal cancers, comprehensive data on esophageal, gastric, and liver cancer burden remain limited. This study examines the global burden of esophageal, gastric, and liver cancers in 2022 and analyzes the trends of age-standardized incidence and mortality rate (ASRs) in China from 2000 to 2018, thereby providing evidence for the formulation of cancer control strategies. Methods: The global burden of esophageal, gastric and liver cancers including the estimated number of cases and deaths and the ASRs for incidence and mortality were from GLOBALCAN 2022 dataset. Data from 22 cancer registries in China were employed for the trend analysis of the ASRs for incidence and mortality of these three cancers. The Joinpoint model was used to compute the average annual percentage change (AAPC) of the incidence and mortality of the three cancers from 2000 to 2018. Results: Globally, esophageal, gastric and liver cancers accounted for 11.8 % of incident cancer cases and 19.1 % of cancer deaths. China bore a disproportionately high burden, representing 43.8 %, 37.0 %, and 42.4 % of global esophageal, gastric, and liver cancer cases respectively, and 42.1 %, 39.4 %, and 41.7 % of corresponding deaths. However, the ASRs for incidence and mortality for all three cancers declined significantly in China (2000-2018), with absolute case numbers decreasing for gastric and esophageal cancers during 2010-2022. Age-specific analysis revealed most pronounced declines in incidence and mortality in populations under 40 years old, with AAPCs of less than -6.0 % for esophageal cancer, around -4.0 % for gastric cancer, and approximately -2.0 % for liver cancer. Conclusions: China has achieved remarkable progress in controlling esophageal, gastric and liver cancers, yet these malignancies remain major public health challenges. Future efforts should intensify existing prevention measures while expanding screening programs, particularly for aging populations. These findings offer valuable insights for regions undergoing similar epidemiological transitions.

Indexed as

Average annual percent changeEsophageal cancerGastric cancerGlobal burdenLiver cancerTrends

Identifiers

PMID40693238
PMCPMC12276617

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.